Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's …

Dec 30, 2024 · Axsome Therapeutics' drug led to a 13.8-point improvement in symptoms as measured by a 203-point scale called the Cohen-Mansfield Agitation Inventory, or CMAI. The placebo group had a similar 12.6 ...

12%
OFF

Axsome Reports Mixed Results For Alzheimer's Agitation Drug

2 weeks from now

Dec 30, 2024 · Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the treatment of agitation in Alzheimer's disease …

seekingalpha.com

FAQs about Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's … Coupon?

Does Axsome Therapeutics have Alzheimer's disease agitation?

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. Please watch the video at Investors.com - How To Sell Stocks: When To Cut Losses Agitation is a common symptom of Alzheimer's disease which can cause a patient to feel restless, worried and unable to settle down. ...

Is AXS-05 a safe treatment for agitation in Alzheimer's patients?

The company noted that results for the primary and nearly all secondary endpoints numerically favored AXS-05 over placebo, according to a statement. Axsome (AXSM) said the results support the efficacy and safety of AXS-05 in the treatment of agitation in Alzheimer's patients. ...

Does AXS-05 delay relapse in patients with Alzheimer's disease?

The ACCORD-2 Phase 3 trial achieved the primary endpoint with AXS-05 statistically significantly delaying the time to relapse of agitation, assessed by the Cohen-Mansfield Agitation Inventory total score, in patients with Alzheimer’s disease compared to placebo, demonstrating a 3.6-fold lower risk of relapse compared to placebo. ...

Will auvelity be approved in Alzheimer's disease agitation?

While Auvelity has a chance to be approved in Alzheimer’s disease agitation with the positive data from ADVANCE-1 along with ACCORD-1 and ACCORD-2, it is unclear how the FDA will view the withdrawal studies, says the analyst, who believes that investors “will be somewhat skeptical of approval,” but maintains an Outperform rating on Axsome shares. ...

Is agitation a symptom of Alzheimer's disease?

Agitation is a common symptom of Alzheimer's disease which can cause a patient to feel restless, worried and unable to settle down. In one study comparing Axsome's AXS-05 to a placebo, patients showed a 3.6-fold lower risk of relapsing into agitation. But a second five-week study didn't pass muster. ...

Does AXS-05 prevent relapse?

The study also met the key secondary endpoint of relapse prevention. The study also showed AXS-05 reduced worsening for overall Alzheimer’s disease severity compared to placebo, Axsome (NASDAQ:AXSM) added. ...